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Abstract
Remote patient monitoring should reducemortality rates, improve care, and reduce costs.We present an overview of the available
technologies for the remote monitoring of chronic obstructive pulmonary disease (COPD) patients, together with the most
important medical information regarding COPD in a language that is adapted for engineers. Our aim is to bridge the gap between
the technical and medical worlds and to facilitate and motivate future research in the field. We also present a justification,
motivation, and explanation of how to monitor the most important parameters for COPD patients, together with pointers for
the challenges that remain. Additionally, we propose and justify the importance of electrocardiograms (ECGs) and the arterial
carbon dioxide partial pressure (PaCO2) as two crucial physiological parameters that have not been used so far to any great extent
in the monitoring of COPD patients. We cover four possibilities for the remote monitoring of COPD patients: continuous
monitoring during normal daily activities for the prediction and early detection of exacerbations and life-threatening events,
monitoring during the home treatment of mild exacerbations, monitoring oxygen therapy applications, and monitoring exercise.
We also present and discuss the current approaches to decision support at remote locations and list the normal and pathological
values/ranges for all the relevant physiological parameters. The paper concludes with our insights into the future developments
and remaining challenges for improvements to continuous remote monitoring systems.
Keywords Remote patient monitoring . Telehealthcare . Telemedicine . Telehealth . eHealth . Chronic obstructive pulmonary
disease . COPD . Patch ECG . Transcutaneous measurement . Decision support in healthcare
1 Introduction
According to the World Health Organization (WHO) [1],
chronic obstructive pulmonary disease (COPD) is currently
the fourth, and will soon become the third, most frequent
cause of death worldwide. It is also a disabling disease and
therefore associated with high costs for treating and managing
patients.
At the same time, it is well known that remote patient
monitoring can significantly reduce healthcare costs [2].
Such remote monitoring is very applicable to COPD patients,
and there is evidence that it reduces costs [3] by at least 14%
[4]. However, there are still no widely accepted remote mon-
itoring services involving recently developed sensors that use
available technologies efficiently. Currently, COPD patients’
physiological parameters are not continuously monitored
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outside hospitals, except for research purposes. Symptoms are
typically reported by the patients themselves using paper-
based diaries.
COPD patients are usually outpatients, except in cases
of exacerbation (sudden worsening of their health status,
which happens on average one to four times per year), for
which they might be hospitalized. More than 70% of
COPD-related healthcare costs are consequences of emer-
gency and hospital stays for the treatment of exacerba-
tions [5]. On the other hand, remote monitoring can re-
duce the frequency and severity of COPD exacerbation
symptoms [6], and consequently reduce the costs.
Moreover, there are studies that investigate the suitability
of home care for severe, uncomplicated exacerbations [7].
Even though economic aspects are important, the primary
goal of remote monitoring is an improvement in the level of
care. Based on 10 trials, McLean et al. showed in a Cochrane
systematic review that telehealthcare can increase the quality
of life for COPD patients, estimated by the St. George’s
Respiratory Questionnaire (SGRQ) [8], and reduce the num-
ber of exacerbations and emergency hospitalizations [9]. The
authors defined the term telehealthcare as follows: Bhealthcare
at a distance, involving the communication of data from the
patient to the health caregiver, usually a doctor or nurse, who
then processes the information and responds with feedback
about the management of the illness.^
The terms telemonitoring and telemedicine are probably
the most often used synonyms for telehealthcare, even though
the term telemedicine most often refers only to communica-
tions between healthcare providers [10]. The two terms are
used by Paré et al. [11, 12] and Bashshur et al. [13], respec-
tively, in their reviews that demonstrate the usefulness of re-
mote monitoring in chronic diseases in general. A recent re-
view by Lundell et al. showed evidence that Btelehealthcare
may lead to improvements in physical activity level^ for
COPD patients [14].
A review by Pedone and Lelli [15], including an investiga-
tion involving 256 patients in the UK [16] that employed
SGRQ and oxygen saturation monitoring, showed the positive
but not significant effect of telehealthcare on hospital admis-
sions and emergency room (ER) visits. In agreement,
McDowell et al. [17] showed that home-based healthcare with
telemonitoring improves the SGRQ score, but did not provide
any significant improvement in ER visits, hospital admissions,
and exacerbations, and was not even cost effective.
In conclusion, the evidence for telehealthcare’s effective-
ness is mixed and not conclusive, but the studies in general
show an improvement or at least an equivalence with the
standard care, without differences in mortality rates (except
for the review by Polisena et al. [18], which showed higher
mortality rates in the Btelephone-support^ group).
These studies of telehealthcare focus mostly on the use of
communication technologies, like telephone and internet, to
communicate with healthcare professionals from home, in-
stead of the usual face-to-face care, whereas the physiological
data and symptom self-reporting are transmitted and analyzed
on a daily basis. As such, telehealthcare is a subset of Bremote
monitoring^ as we define it, which also encompasses auto-
matic continuous physiological data transmission and pro-
cessing, decision support, the prediction of deteriorations,
and alarming. Therefore, we can expect that remote monitor-
ing, as it develops over time and involves more measured
parameters and more sophisticated decision support algo-
rithms, will be more efficient than telehealthcare is today.
In recent years, the developments in remote monitoring
solutions have been intensive. Consequently, there are a num-
ber of different devices that can be used for monitoring the
physiological, behavioral, and environmental parameters for
COPD patients [19]. However, there are still various chal-
lenges when it comes to obtaining all the significant sensory
inputs, and about how to merge and fuse the data coming from
different sources and sensors, for the purposes of providing
the input to a decision support system that should provide
efficient early detection, prediction, and alarms for medical
personnel or other healthcare providers. The most important
task of any alarm system is to detect common life-threatening
events in a timely manner, in order that an effective treatment
is possible.
We see four possibilities with respect to the remote moni-
toring of COPD patients: (1) continuously monitoring during
normal daily activities for the early detection of exacerbations
and life-threatening events, (2) during the home treatment of
mild exacerbations, (3) for monitoring oxygen therapy, and
(4) for monitoring exercise.
With respect to the technology used, most of the previous
efforts related to enabling the remote monitoring of COPD
patients focused on using the self-reporting of symptoms,
pulse oximetry, and spirometry [20, 21]. Medical justifica-
tions for the choices in sensory inputs will be explained in
the continuation, together with the current state of the art.
Pulse oximeters, however, cannot detect changes in the arte-
rial carbon dioxide (CO2) partial pressure (PaCO2), which we
argue is one of the most significant parameters for COPD
patients. The PaCO2 is currently obtained invasively by tak-
ing blood samples at discrete time instants. To motivate an
improvement, this paper justifies PaCO2 monitoring for
COPD patients continuously and noninvasively by transcuta-
neous CO2 measurements (PtcCO2). We also discuss and jus-
tify the role of cardiac electrical activity, i.e., electrocardio-
gram (ECG) monitoring. PtcCO2 and ECG have not been
used significantly so far, even though they are two crucial
physiological parameters for the remote monitoring of
COPD patients. There are currently specific scientific and
technological challenges for the continuous remote monitor-
ing of the PtcCO2 and ECG, which will also be discussed and
explained in the continuation.
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2 Chronic obstructive pulmonary disease—a
short description for engineers
COPD is a chronic and progressive respiratory disease for
which there is no cure for the cause of the disease, but there
are a number of therapeutic approaches for relieving the
symptoms and slowing the progression of the disease. It pre-
sents as a combination of signs and symptoms, of which
breathlessness, excessive sputum production, reduced exer-
cise tolerance, and a chronic cough are the most common.
The main causes of COPD are tobacco smoke (the prevalent
cause), respiratory infections, air pollution, dust, and
chemicals in poorly ventilated areas.
The pathology of COPD affects the large airways, the small
(peripheral) bronchioles, and the lung tissue itself. The normal
inflammatory response in the aforementioned clinical condi-
tions is amplified in people prone to COPD development. The
pathophysiologic mechanisms are not clear and are most like-
ly diverse. Increased numbers of activated polymorphonuclear
leukocytes and macrophages release elastases, the enzymes
responsible for degradation, in a manner that cannot be
counteracted effectively, resulting in destruction of the lung
[22]. As a consequence of the destroyed alveolar walls, the
total respiratory surface area responsible for gas exchange is
reduced. In addition, the increased airflow resistance in the
large and small airways causes difficulties with breathing, air
trapping in the lung, and hyperinflation of the lung. The air
trapped within the destroyed lung forms large air pockets that
are poorly ventilated (areas with perfusion but no ventilation).
The impaired regional ventilation causes a ventilation-
perfusion (V/Q) mismatch.
Easily noticeable physiological consequences are difficulties
in exhaling and breathlessness. In patients with severe COPD,
poor sleep quality is often reported [23]. Exacerbation episodes
are important and are the triggers for bacterial or viral infec-
tions, necessitating antibiotic treatment.
In patients that smoke, the cessation of tobacco use is man-
datory. In fact, this is the only intervention that definitely
slows the development of COPD. When the disease is diag-
nosed, vaccination against influenza and pneumococcal pneu-
monia is recommended, since influenza is the most important
cause of excess mortality. As an anti-inflammatory treatment
for patients with frequent exacerbations, inhaled or oral corti-
costeroids are usually prescribed for short intervals. A possi-
ble additional therapy is pulmonary rehabilitation (a compre-
hensive program that combines exercise training, smoking
cessation, nutrition counseling, and education) followed by a
home exercise program and/or by repeated pulmonary
rehabilitations.
Another common therapeutic intervention is home oxygen
admission, each day for at least 15 h, to ensure the maximum
benefit [24] (also during sleep), or at least during planned
exercise, where there is evidence that it improves exercise
performance [25] and endurance [26]. This long-term oxygen
therapy (LTOT) improves the survival rates for COPD pa-
tients with low arterial oxygen partial pressure (PaO2) (less
than 7.3 kPa (55 mmHg)) [27]. LTOT can improve outcomes
other than mortality, including quality of life, cardiovascular
morbidity, depression, cognitive function, exercise capacity,
and frequency of hospitalization [28]. Oxygen in LTOT is
delivered to the nose with nasal cannulas (prongs). The draw-
backs of LTOT are that it additionally reduces the mobility of
patients, can increase levels of CO2 in the blood stream, and
entails a risk of burns and starting fire for patients who con-
tinue to smoke, since oxygen supports burning [29].
To prevent death from a lack of oxygen, oxygen is also
commonly administrated in acute COPD exacerbations, most
often by means of non-invasive ventilation (NIV), which in
contrast to LTOT provides a positive pressure during breath-
ing, and is therefore delivered by a mask over nose and mouth
[30]. Another indication for NIV (or even invasive ventila-
tion) is the exhaustion that can be caused by increased work
of breathing.
2.1 Oxygen levels and carbon dioxide retention
in patients with COPD
CO2 and O2 are the gases exchanged between the blood and
the inhaled air during respiration, with CO2 diffusing approx-
imately 20 times faster than O2. The exchange of gases is
compromised in COPD because of the destroyed airways
and lung tissue, which appears as the ventilation/perfusion
ratio (V/Q) mismatch. As a consequence of respiratory failure,
either only the PaO2 is decreased, or both the PaO2 and PaCO2
are abnormal (low PaO2—hypoxemia, high PaCO2—
hypercapnia).
The gold standard for obtained blood-gas partial pressures
and saturations is the arterial blood gas test (ABG), which
involves taking an arterial blood sample and is therefore inva-
sive. Oxygen levels are routinely measured noninvasively by
pulse oximetry, which provides continuous peripheral O2 sat-
uration (SpO2). The SpO2 is usually approximately equal to
the arterial oxygen saturation (SaO2) that is obtained by ABG
(the typical difference is < 2% [31]). The SaO2 and PaO2 are
directly related through the oxygen–hemoglobin dissociation
curve (ODC), which is not fixed and can vary even for the
same person, not only depending on the temperature, PaCO2,
and pH but also depending on some pathological conditions
[31]. On the other hand, PaCO2 is routinely estimated nonin-
vasively from the exhaled breath (end-tidal CO2 pressure
(PetCO2)).
The PetCO2, however, is not a reliable estimate of the
PaCO2 for COPD patients because of physiological reasons
[32, 33], and because the gas needs to be sampled directly at
the patient’s airways [34] which is practically hard to accom-
plish. Fortunately, novel research shows that it is possible to
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reliably estimate the PaCO2 and even PaO2 from transcutane-
ous monitoring [33, 35–46] (PtcCO2 and PtcO2, respectively),
which is not affected by the COPD specificities and is there-
fore reliable for COPD patients. In fact, PtcCO2 has recently
become the preferred method for estimating PaCO2 in remote
settings [32, 33].
Oxygen is commonly administered to patients during
LTOT, but more importantly in acute exacerbations, which
saves lives by preventing severe hypoxemia. Oxygen therapy
can, however, increase the PaCO2, as explained in the next
paragraph. In fact, about a quarter of COPD patients with
acute exacerbations are at risk of hypercapnia if they are given
a high dose of oxygen [47].
It might seem absurd at first glance that oxygen therapy can
cause hypercapnia, but there are several mechanisms respon-
sible for this effect [47]. Here, we mention the most
influential:
& Oxygen-induced deterioration of V/Q matching (see
Fig. 1). As was already mentioned before, COPD is
characterized by V/Q mismatching. There is, however,
a physiological mechanism that is correcting the V/Q
ratio: for alveoli with reduced ventilation (thus reduced
alveolar pO2—partial pressure of oxygen), pulmonary
capillaries supporting these alveoli will constrict, re-
ducing perfusion for the alveoli with reduced ventila-
tion, and consequently improving the V/Q match. In
other words, the delivery of blood is reduced to poorly
ventilated parts of the lung, causing more blood to go
to areas where the gases can be more efficiently ex-
changed. This mechanism is called hypoxic pulmonary
vasoconstriction. The most influential factor for hyp-
oxic pulmonary vasoconstriction is alveolar pO2.
During the oxygen therapy, the pO2, even in alveoli
with low ventilation, will increase, inhibiting hypoxic
pulmonary vasoconstriction. As a result, alveoli with
relatively impaired ventilation will be well perfused,
leading to an increase in V/Q mismatch [48]. Put more
intuitively, a perfusion increase in the lung areas that
are purely ventilated will decrease the efficiency of the
gas exchange and cause an increase in PaCO2.
& Another mechanism for oxygen-induced hypercapnia is
the Haldane effect, which refers to the increased capacity
of deoxygenated hemoglobin to bind and carry CO2, com-
pared to the oxygenated form. Thus, when there is an
abundance of O2, CO2 is released into the blood stream,
causing the PaCO2 to rise [48].
& People with healthy lungs have breathing regulation de-
pendent mostly on changes in blood CO2 levels. Since
some patients with COPD have high levels of CO2 for
long periods of time, the brain’s regulatory breathing cen-
ter can, over time, become less sensitive to CO2 levels, and
more dependent on O2 levels, which causes these patients
to rely more on a low arterial O2 level to stimulate their
breathing. This means that oxygen therapy can reduce the
stimulus to breathe. As a consequence of this reduced
breathing, CO2 removal from the lungs is decreased.
This Bhypoxic drive^ theorem was traditionally widely
accepted, but it was recently challenged at least for the
acute situation, as having only a time-limited effect on
ventilation that cannot explain the total increase in
PaCO2 [48].
Hypercapnia can cause various symptoms, ranging from
mild headaches, lethargy, and confusion, to severe ones with
a hypnotic effect and acidosis with subsequent organ dysfunc-
tion, which can lead to coma and death [47, 49]. It also de-
creases diaphragm contractility and favors muscle fatigue [50].
Clinical signs of hypercapnia are as follows [47]: vasodilation
producing flushing and warm peripheries with dilated blood
vessels (including retinal veins), a bounding pulse (a pulse that
feels full and spring-like on palpation as a result of an increased
thrust of cardiac contraction or an increased volume of circu-
lating blood within the elastic structures of the vascular sys-
tem), drowsiness, flapping tremor, confusion, and coma.
To decrease the risk of hypercapnia induced by oxygen ther-
apy in acute situations, current clinical guidelines recommend
that all patients with COPD receive oxygen therapy targeted at
88–92% SpO2 until hypercapnia is excluded by an ABG anal-
ysis within 1 h of the treatment being started [24, 47]. For some
patients, even very small amounts of supplemental oxygen are
sufficient to worsen hypercapnia, so they might need an even
Fig. 1 Hypoxic pulmonary vasoconstriction and its inhibition by oxygen
therapy. a Normal alveolar ventilation and perfusion. b Reduced
ventilation in the darker alveolus (thus, the local pO2 also drops) causes
reduced perfusion. c Oxygen therapy increases pO2 in all the alveoli,
including the dark one, and inhibits hypoxic pulmonary vasoconstriction
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lower target saturation range [47]. On the other hand, if the
PaCO2 is normal, oxygen therapy can target the usual satura-
tion range of 94–98% and so be more efficient [47].
For the purpose of keeping the SaO2 within a desired range,
pulse oximeters are used in a closed loop to correct for the
administrated oxygen levels. There is clear evidence that this
titrated, and therefore closely regulated, acute oxygen therapy
reduces the mortality and hypercapnia, compared to non-
titrated oxygen therapies [24, 51].
LTOT is also initially titrated for specific needs of each
patient but not during the therapy. The goal of the initial titra-
tion is to reach SpO2 > 90% (resting PaO2 > 8 kPa
(60 mmHg)) without a significant rise in CO2 [52]. This is
done by the ABG analysis, but transcutaneous measurements
can also be used [52].
Although it is widely accepted that oxygen-induced hy-
percapnia can develop during COPD exacerbations, few
studies have reported on PaCO2 changes during LTOT.
Cooper et al. reported a mean PaO2 increase of 3 kPa,
and a mean PaCO2 increase of 0.39 kPa, while patients
were breathing oxygen (30% concentration) [53]. Török
et al. showed increase in PaCO2 during incremental in-
crease of oxygen flow in the initial adjustment of LTOT
but the Brise in CO2 was not considered to be high enough
to lead to a lower prescription of oxygen^ [54]. During
sleep, however, physiological changes occur that cause
the SpO2 to drop for the patients with COPD (nocturnal
oxygen desaturation (NOD)). Since hypoxemia has effects
on the cardiovascular system, NOD could possibly also be
a reason why COPD patients die more during the night
[23]. To counteract NOD, there is a recommendation, in-
consistently applied around the world [55], to increase ox-
ygen flow by 1 l/min during sleep and during exercise (to
counteract the increased need for oxygen during exercise)
[23]. At least one study has reported a significant increase
in PaCO2 due to this increase in oxygen flow [56].
Therefore, at least during sleep, patients could benefit from
titrated LTOT, much like for acute oxygen therapy, but the
patients should also be monitored for hypercapnia [23].
Even though NIV at home is currently not explicitly rec-
ommended for COPD patients [30, 57], it is used instead of
LTOT for specific patients especially in some geographic
areas [58]. In contrast to LTOT, transcutaneous CO2 measure-
ment was studied for NIV at home as an alternative to ABGs
for adjusting NIV settings and was found appropriate [33, 35,
41, 59].
2.2 Relation between COPD and cardiac problems
If low oxygen levels are present for longer periods of time
(chronic hypoxemia), they can result in hypoxic pulmonary
vasoconstriction (Fig. 1). On the other hand, the destruction of
lung tissue leads to a breakdown of the pulmonary capillaries,
and hence a reduction of the pulmonary vascular system.
These two mechanisms cause an increased resistance of the
pulmonary vascular system to the blood stream. The increased
resistance causes an increase in the pulmonary artery pressure
and makes it harder for the heart to pump blood to the lungs. If
this condition continues, it can cause the heart muscle to grow
in size (right ventricular hypertrophy) and eventually lead to
failure of the right side of the heart [60].
It takes time to develop right-side heart failure, but the heart
remodeled with hypertrophy, and receiving hypoxemic blood
for its own nutrition, is very prone to arrhythmias and sudden
cardiac events. On the other hand, hypercapnia decreases
myocardial contraction [61] and also predisposes to arrhyth-
mias [62]. Furthermore, COPD occurs frequently with coro-
nary artery disease [63]. For all these reasons, a substantial
proportion of the deaths in patients with COPD is the result of
cardiovascular complications [63–65].
In general, cardiovascular diseases are the most frequent
comorbidities with COPD and include the following entities:
coronary artery disease, heart failure (about 30% of patients
with stable COPD show some degree of heart failure), arrhyth-
mias, and hypertension (one of the most frequent comorbidi-
ties in COPD) [63, 66].
2.3 Physical activity in COPD
Regular physical activity (PA) is recommended for all patients
with stable COPD [66]. Walking is generally accepted, but
also stair-climbing, treadmill, or cycling exercises are benefi-
cial. Pulmonary rehabilitation (supervised exercise) or a home
exercise program can improve the lung’s functional status.
PA in COPD patients decreases the risk of hospitalization
[67], reduces the decline in lung function [67], but can also
improve the general health status and decrease both disability
and mortality [68, 69].
PA is drastically reduced during and after hospitalization
caused by exacerbation, but even patients with milder exacer-
bations, which do not require hospitalization, tend to stay
indoors during the exacerbation period, which lowers PA
levels [67]. It might take a number of weeks for patients to
recover from exacerbation, during which time they lose mus-
cle mass as a result of reduced activity.
Patients whose arterial PaO2 are borderline at rest may
develop worsening hypoxemia during exercise, but even pa-
tients without hypoxemia may improve exercise capacity with
supplementary oxygen [26]. During exercise, a substantial
CO2 retention (PaCO2 increase of more than 4 mmHg) may
also occur frequently in patients with COPD, and can even
result in exercise-induced hypercapnia (an elevation of PaCO2
levels greater than 45 mmHg (6.0 kPa). Less frequent is a
significant reduction of PaCO2 on exertion which can go even
to hypocapnic levels [70].
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2.4 COPD exacerbations
BAn exacerbation of COPD is an acute event characterized by
a worsening of the patient’s respiratory symptoms that is be-
yond normal day-to-day variations and leads to a change in
medication^ [66]. In plain language, patients cannot catch
their breath. Such exacerbations are the major cause of
COPD patients’ hospitalization, but are also associated with
deteriorations of the patients’ health-related quality of life
[71], contribute to a long-term decline in lung function [72],
and have an independent negative impact on the patients’
prognosis [73]. Additionally, mortality increases with the fre-
quency of severe exacerbations, particularly if these require
admission to a hospital [73].
Early recognition of exacerbation symptoms and prompt
treatment improves recovery rates, reduces the risk of hospital-
ization, and is associated with a better health-related quality of
life [74]. It is therefore beneficial to detect the first signs of
exacerbations or to predict them so that the patients can be
appropriately treated in a timely manner and optionally to be
prioritized by home healthcare professionals. Nevertheless, if
the exacerbations happen despite the preventative efforts, some
of the patients, depending on the exacerbation severity, could
still be treated at home for uncomplicated exacerbations [7, 75],
since these exacerbations would not require an intensive inves-
tigation or complex therapy. According to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) strategy docu-
ment [30, 66], more than 80% of exacerbations can bemanaged
on an outpatient basis. Concordantly, the European Respiratory
Society published a consensus statement stating that Bmost
exacerbations are mild and can be treated on an outpatient basis
(home care).^ Severe events should be evaluated in the emer-
gency department of a hospital, so that the patient can be ad-
mitted, if necessary. If the severity of an episode is in doubt, the
assessment should take place in a hospital. In a very severe,
life-threatening episode, direct admission to an intensive care
unit (ICU) is indicated [76].
In the case of home care, the patients can be periodically
visited by respiratory nurses who monitor treatment compli-
ance and progress. The treatment at home can be leveraged
and made more efficient and secure by using continuous re-
mote monitoring.
3 Existing devices and technologies suitable
for the remote and continuous monitoring
of COPD patients
The monitoring of patients is supported by research and de-
velopment in sensor technology, which has resulted in various
wearable and unobtrusive sensors. These sensors are capable
of monitoring physical activities and measuring physiological
and biochemical parameters like electrocardiogram (ECG),
heart rate (HR), blood pressure, PaO2, and body temperature
[19]. There are two possibilities for unobtrusive remote mon-
itoring: sensors can either be worn by the monitored subject or
embedded in the monitored subject’s environment. Currently,
noncontact sensing is prone to a low signal-to-noise ratio and
is therefore not considered in this paper.
3.1 Transcutaneous O2 and CO2 monitoring
Various devices offer the possibility to simultaneously moni-
tor the level of oxygenation and CO2, combining either SpO2
with PtcCO2 (e.g., SenTecTM, Therwil, Switzerland [37], and
TCM ToscaTM, Radiometer, Neuilly Plaisance, France [77]),
or transcutaneous PtcO2 with PtcCO2 (e.g., TCM Combi
MTM, Radiometer, Neuilly Plaisance, France [77]).
3.2 Cardiac electrical activity (ECG) remote monitoring
Holter monitors are traditionally used for ECG acquisitions in
remote settings, but they are being superseded by wireless bi-
potential patch devices [78–80], whose development has been
intensive in recent years (a representative example, a Savvy
patch ECG sensor, is shown in Fig. 2). The patch ECG
(PECG) sensors are already established as patient friendly,
well tolerated, unobtrusive, wire free, and with recording ca-
pabilities that span from weeks to months (much longer than
standard Holter monitors), which is beneficial for detecting
potentially malignant arrhythmias that take a longer time to
detect. They provide good adhesion to the skin, and some of
them even claim to be waterproof.
The Savvy monitor has been certified as a medical
device according to the directive MDD 93/42/EEC, and
standards EN 60601 and EN ISO 14971, and has recently
Fig. 2 A prototype of a patch ECGmonitor developed at the Jožef Stefan
Institute, Ljubljana Slovenia [81, 82], with two self-adhesive disposable
electrodes, a lithium coin battery, micro-processor, BT4 radio, and printed
circuit board antenna (up). Savvy sensor, the final product (down)
552 Med Biol Eng Comput (2018) 56:547–569
become available on the market, while the ZIO® XT
Patch by iRhythm Technologies, Inc. and SEEQ™ MCT
patch device by Medtronic, Inc. have already been exten-
sively evaluated. The evaluations show evidence of an
increased diagnostic lead in both adult and pediatric pa-
tients compared to Holters [79]. There are also other
PECGs available on the market, and the number is expect-
ed to increase in the future [78–80].
3.3 Respiratory rate
One of the signs of COPD exacerbation is a respiratory rate
(RR) over 25/min (see Sect. 4.7). Furthermore, there is evi-
dence that a change in RR has a strong predictive power for
exacerbation [83, 84].
The respiratory effort can be captured by an impedance
pneumograph, stretch sensors, and flow thermography,
which captures breathing from the temperature difference
between the inhaled and exhaled air. The impedance
pneumogram is the most common method used in hospitals
[85]. Its basic principle is to inject current into the tissue by
employing two drive electrodes placed on the chest and to
measure the potential difference between the two points.
The potential difference is related to the impedance of the
tissue, which varies with respiration.
The respiration also affects the cardiovascular physiology.
Consequently, the RR can also be estimated from the ECG
and pulse oximetry. Even though it is inferior to the ECG-
derived RR, pulse oximetry can also provide a reliable RR
[86]. Indeed, recently, the Nellcor Respiration Rate System
received CE mark approval. In addition to SpO2, and HR
monitoring, it also provides RR, and all this is obtained from
a single finger sensor [87].
3.4 Pulse oximetry
Pulse oximetry is the continuous measurement of saturation
for peripheral oxygen (SpO2). A clip-like device is placed on a
thin body part, most commonly on a finger, but also on an ear
lobe, or across a foot if applied on infants. There are a number
of inexpensive and easy-to-use pulse oximetry devices avail-
able on the market.
The basic principle is to emit two different wavelengths
from one side of the body part using a pair of small, light-
emitting diodes and measure the amount of light that
passes through the body with a photodiode placed on
the other side. The two wavelengths are chosen so that
their absorption (the emitted minus the passed-through
light) is significantly different for the oxygenized and
not-oxygenized hemoglobin. The SpO2 is calculated from
the ratio of the two measurements.
3.5 Nutrition and weight monitoring
Both obesity and loss of body mass are commonly encoun-
tered with COPD [76]. Malnutrition is associated with respi-
ratory muscle dysfunction and increased mortality. Therefore,
nutritional intervention should occur if a large loss of body
mass is detected. Nutritional interventions aimed at achieving
an ideal body weight are also recommended. High-
carbohydrate diets and an extremely high caloric intake should
be minimized to reduce the risk of excess CO2 production
[76]. Furthermore, obesity contributes to breathlessness in
some individuals due to affected diaphragm mobility. On the
other hand, weight loss is associated with a more severe im-
pairment of the lung function [76].
3.6 Blood pressure measurement
The justification for measuring blood pressure comes from the
fact that hypertension is a frequent comorbidity in COPD [66],
but can also be caused by corticosteroid therapy. BBlood
pressure^ normally refers to the arterial pressure in the sys-
temic circulation. There are also measurements of pressures in
the venous system and pulmonary vessels, but these require a
catheter and are therefore beyond the scope of this paper.
The arterial blood pressure is noninvasively routinely mea-
sured by the auscultatory method involving an inflatable cuff
wrapped around the arm, a manometer measuring the pressure
in the cuff, and a stethoscope placed over the brachial artery at
the elbow. There is also the oscilometric method, which is
more suitable for automatic measurements in home environ-
ments [88]. The oscilometric method also uses a cuff. There
are also continuous, noninvasive arterial pressure-monitoring
devices that measure in real time, completely noninvasively
and without cuffs. These devices are, however, still to prove
their precision [89]. An overview of experimental blood pres-
sure measurement devices is provided in [90].
There are a number of devices available on the market that
can be used for the remote automatic monitoring of blood
pressure (mostly oscilometric) that patients can use without
assistance. For specific guidelines on how to measure blood
pressure remotely at home, the reader can refer to [88].
3.7 Spirometry
Diagnostic spirometry measures the volumes of air inspired
and expired by the lungs to assess a patient’s lung function for
the purposes of comparison with a patient population or with
previous measurements from the same patient. The presence
of airflow limitation is recognized by a reduction in the ratio
FEV1/VC or the ratio FEV1/FVC, where VC (vital lung ca-
pacity) is the maximum amount of air expired from the fully
inflated lung, FVC (forced vital capacity) is the forced amount
of air a person can exhale after the maximum inspiratory
Med Biol Eng Comput (2018) 56:547–569 553
effort, and FEV1 (forced expiratory volume in 1 s) is the frac-
tion of the FVC expired during the first second (see Fig. 3).
The presence of a post-bronchodilator FEV1/FVC of less than
0.7 confirms the presence of COPD [66]. The FEV1/VC ratio
is a relatively sensitive index of mild COPD. In moderate-to-
severe cases of the disease, however, the severity of the air-
flow limitation is best assessed by the FEV1 in relation to
reference values (also known as predicted values) [91].
Spirometry is used mainly in the diagnosis of COPD, as
well as in the assessment of its severity, progression, and
prognosis, but it is not suitable for acute states. Patients with
acute severe exacerbations of COPD can be too breathless to
undertake spirometry testing, but in any case, conducting spi-
rometry in acute situations is not very informative [66].
Due to the growing number of patients, the diagnosis of
COPD should take place in general practices that are equipped
with spirometers. For the diagnosed patients, the spirometry
should be carried out at least once per year to identify patients
with a rapid decline in lung function [66]. To ensure quality,
the spirometry should be carried out by nurses who have been
trained in how to perform spirometry [92].
Portable handheld spirometers available on the market can
bemore or less accurate compared with conventional hospital-
based equipment [92]. Still, the technology used in portable
spirometers is constantly evolving, which means their perfor-
mance is constantly improving [92]. Regardless of the device
accuracy, the measurements obtained by patients on their own
need to be taken with caution when supplied to a decision
support system, and cannot be used as a substitute for the
diagnostic spirometry [92].
Also beneficial are peak expiratory flow (PEF) meters,
which are simpler and cheaper than spirometers. If we strictly
apply our definition of spirometry, PEFmeters are not spirom-
eters because they measure only the maximum speed of
expiration, not the volume of expired air. The PEF meters
are successfully used in asthma monitoring, with high patient
compliance, but they are beneficial in COPD monitoring as
well. A value for PEF of less than 100 l/min is a sign of acute
COPD exacerbation (see Sect. 4.7). Additionally, van den
Berge et al. presented evidence that PEF is a predictive factor
for exacerbation [93], whereas Inglesia et al. showed that PEF
has an important predictive value for determining the risk of
death in patients who required hospitalization for acute exac-
erbation of COPD [94].
3.8 Thermometry
Normal body function depends on a relatively constant body
temperature. A body temperature higher than 38.5 °C is one of
the parameters indicating severe exacerbation [76].
Most common sites used to obtain body temperature read-
ings with medical thermometers are the anus (rectal tempera-
ture), the mouth (oral temperature), under the arm (axillary
temperature), and the ear (tympanic temperature).
Oral and rectal body temperatures, although slightly differ-
ent, correlate well with the core body temperature. The most
easy to apply continuous temperature measurement devices in
remote settings, i.e., those that can be placed on the body
surface (axillary and tympanic), do not follow the core body
temperature well enough to recommend their use [95].
3.9 Environmental sensors
Environmental sensors are present in the patients’ environ-
ments or are embedded into objects in the environments, like
chairs, seats, mattresses, mirrors, toilet seats, and bathroom
scales.
Sensors that measure environmental temperature and air
quality can be used to assess the condition of patients’ living
environments. There is evidence of a significant positive cor-
relation between quality of life and air quality [96]. Air pollu-
tion has been shown to be a major COPD risk factor [97], but
numerous other diseases can be caused by air pollution. Since
most COPD patients are past or current smokers, it is quite
informative to detect smoking. Smoking in combination with
oxygen therapy is dangerous due to the risk of fire.
3.10 Personal computing devices
Data measured with physiological and environmental sensors
can be preprocessed by the sensors (e.g. the R-R interval
lengths can be extracted from a measured ECG). Either the
results of preprocessing, or the raw signals, or both can be
wirelessly transferred to the users’ personal computing de-
vices (PCDs), such as smartphones, tablets, or smart watches.
On PCDs, the data can be further processed, most importantly
for detecting life-threatening events, or for some specific
Fig. 3 Representative spirograms (expired volume–time curves) for
healthy subjects (FEV1/FEV ~ 4.6/5.8 = 0.8) and subjects with COPD
(FEV1/FEV ~ 1.7/3.4 = 0.5)
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purposes, which in the case of an ECG can be, for example,
synthesizing a 12-lead ECG [98], or extracting the breathing
rate from an ECG [99]. Modern PCDs already contain a num-
ber of sensors, e.g., microphone, camera, GPS, and acceler-
ometer. The obtained physiological signals can be integrated
with the PCDs’ sensing abilities to extract relevant features
that can be used as inputs for a decision support system run-
ning on the same device. From there on, the raw signals and/or
the results of the processing can be forwarded to the cloud for
further processing and storage [100]. The general concept of a
remote monitoring system is presented in Fig. 4.
3.11 Previous research on systems
for the telemonitoring and self-management of COPD
Self-management is not universally defined, but the most gen-
eral meaning of the term is the patients’ ability and skills to
deal with their chronic diseases [101, 102]. In the case of self-
management, patients are contacting medical professionals,
whereas in telemonitoring, the communication is bidirectional
and the medical personnel can initiate communication with
patients or their caregivers.
A number of systems combine self-management and
telemonitoring [20, 103]. Most of them focus on enabling
patients to self-assess their status (see Sect. 4.5) and record
pulse oximetry on their own. Some systems combine pulse
oximetry with an RR sensor, blood pressure monitor, activity
monitors, and less frequently some other sensors [20]. In al-
most all the systems, the data is transmitted on a daily basis.
When a deterioration in health occurs, patients can contact the
healthcare professionals or be contacted via telephone calls.
There are two available reviews covering the existing tech-
nology in COPD telemonitoring [20, 21], whereas the others,
already mentioned in the introduction, focus on clinical out-
comes (e.g., mortality and quality of life), reduction in
healthcare service utilization, feasibility and use, and on the
economic and organizational impacts of telemonitoring.
Among the existing research, there is a lot of variability and
a lack of consensus. For instance, different questionnaires
were used as well as different threshold values for physiolog-
ical parameters [21]. There is not even a consensus about what
constitutes an exacerbation [104]. Efficient decision support
algorithms have only been applied in a minority of studies.
The need to establish a scientifically sound methodology
that is agreed on and accepted by future studies is obvious
[104]. To facilitate this, in the continuation, we will identify
and justify the application of the most significant technologies
and sensory inputs (together with their pathological ranges)
for the remote monitoring of COPD patients, review the cur-
rent status of decision support systems, and present the re-
maining challenges.
4 Scientific and technical solutions
and challenges in monitoring COPD patients
4.1 Monitoring PaCO2
Since oxygen therapy can increase PaCO2, as explained in
Sect. 2.1, it is beneficial to monitor PaCO2 not only during
acute oxygenation therapy but also possibly during LTOT
(especially during sleep [23]) (see Sect. 2.1). Mortality in
acute exacerbations of COPD was reported to be associated
even with an increase in chronic stable levels of PaCO2 [51],
which shows that it is also beneficial to regularly monitor
stable (baseline) CO2 levels.
The standard for obtaining PaCO2 is ABG, which is an
invasive procedure with risks, but also painful, time consum-
ing, and discrete. Even though not perfectly following the
PaCO2 obtained by ABG, transcutaneous monitoring has its
advantages: it is painless, noninvasive, and continuous, with
almost no sleep disturbance, and possibly self-manageable. It
is therefore possible to use PtcCO2, along with pulse oximetry,
instead of ABG, for titrating any oxygen therapy. Moreover,
since PtcCO2 is continuous, the titration can be without delay.
PtcCO2 is not measured routinely in remote settings due to
the lack of inexpensive PtcCO2 monitors. Even though it is
likely that the prices of PtcCO2 monitors will reduce over
Fig. 4 General architecture of
remote monitoring systems
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time, as happens with all electronic devices, an open question
is how to compensate for the currently high prices. One pos-
sibility is for PtcCO2 monitors to be used by medical person-
nel that periodically visit multiple COPD patients for the pur-
pose of monitoring the baseline PaCO2 regularly, and/or in the
minutes after the onset of oxygen therapy. This entails a need
for a new software system that will keep track of each patient’s
measurements and integrate them with electronic health re-
cords. Another possibility is for the same device to be shared
between multiple patients for periodic use during 1 day and
night. This would be enough to access how the PaCO2 chang-
es during the LTOT, which is particularly important during the
night, as explained in Sect. 2.1.
One current weakness associated with transcutaneous mea-
surements is the approximate 2-min lag time for the PaCO2
changes to be reflected in the PtcCO2 [105]. An open scien-
tific question is could the changes in PaCO2 be predicted to
compensate for the lag?
It has been suggested that patients who are known to be at
risk of hypercapnic respiratory failure should be given oxygen
Balert cards^ and should be instructed to show these cards to
medical personnel [24, 47]. The purpose of the cards is to
warn medical personnel that the patients should be given con-
trolled rather than high-concentration oxygen therapy and to
adjust the therapy based on the previous ABG results stored
on the card because hypercapnic respiratory failure can occur
even if the targeted SaO2 is below 88%. It is important to
investigate how this digital alert card can be employed in a
convenient form, like, for example, as a smartphone applica-
tion, which could be accessible to medical personnel even if
the patient is not capable of presenting the alert card on his/her
own.
4.2 ECG, ECG-derived RR, and HR
Reports show that the primary cause of death for COPD pa-
tients is cardiac failure [64, 65]. Myocardial infarction is the
co-morbidity with the greatest potential for treatment and pre-
vention to improve the prognosis of COPD patients [64]. In
general, cardiovascular diseases are the most frequent and
important diseases coexisting with COPD (see Sect. 2.2.) It
is therefore of the greatest importance to continuously monitor
cardiac electrical activity for patients at risk, and issue alarms
when dangerous event are detected.
Recent developments in ECG technology have resulted in
PECGs that possess convenient features for remote monitor-
ing (see Sect. 3.2). They are small and wireless. Patients can
place them on their own, freely sleep with them, and even take
a shower.
They are most often single lead devices. One lead is
enough to provide HR [106] which can be used to detect
arrhythmias and cardiac arrest. Some arrhythmias need to be
terminated instantaneously (see Sect. 5.4); therefore, it is
crucial in that situation for a system of remote monitoring to
alert people in the vicinity of the patient and direct them to the
nearest defibrillator (which are becomingmore and more pres-
ent in the environment). PECGs can also be used to obtain
specific indicators, like heart rate corrected QT interval (see
Sect. 5.4), relevant for COPD patients.
It has also been shown that reliable RR can be estimated
from ECGs produced by them [99], which eliminates the need
for separate respiratory sensors. This is of additional signifi-
cance for COPD patients, since RR is one of the major param-
eters for detecting COPD exacerbations (see Sect. 4.7).
Figure 5 shows how RR can be extracted from amplitude-
modulated ECG signal obtained using a PECG. For details of
the algorithm used, see [99]. Respiration modulates the ECG
also in terms of HR (respiratory sinus arrhythmia (RSA)).
Even though it has been shown that extraction from HR pro-
vides a good approximation of the mean RR if the time series
is longer than 1 min for young supine subjects, it is signifi-
cantly less accurate for elderly people [107]. There are also
other approaches for extracting the RR from ECG. For a re-
cent evaluation of four different methods, i.e., filtering, R and
RS amplitude, and QRS areas, please refer to [108].
Since they are still not a part of standard clinical care (and
consequently not shared among patients) and are not covered
by health insurance, the disadvantage of the PECGs is that
they have high cumulative consumer costs. Moreover, the
customers can be dependent on the device company for raw
and aggregated data retrial.
The crucial current deficiency of PECG sensors is the data-
processing time, which can be after the recording (ZIO XT) or
after the transmission to the company’s data networks
(SEEQ), where the processing time depends on the processing
abilities of the company’s data center. The Savvy sensor, how-
ever, comes with stand-alone computer software for a basic
analysis of the acquired ECG that a customer can use on his/
Fig. 5 Interval of an ECG (red) measured with a patch ECGmonitor, and
respiration intervals (black) measured by a thermistor near the front of the
nose. The amplitude of the measured ECG signal varies with respiration.
All nine respiration intervals are identified (blue circles). The presented
results come from a study reported in [99]
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her own. The data analysis algorithms that can run directly on
the PECG sensor have just recently started to be developed, an
example being the HeartSaver reported in [109].
Since acute life-threatening events are the most important,
it is obvious that there is a need for further developments to
enable wireless monitors that can not only record ECG to
estimate the arrhythmia burden but more importantly detect
life-threatening events in real time and send an alarm to the
relevant stakeholders for a timely diagnosis and treatment.
Even though PECG sensors detect more reportable events
than Holter monitors, largely because of the significantly longer
recording times, there is evidence that Holter monitors detect
more events in the same period of time [79]. This might be
because Holters are multichannel devices, but also due to the
differences in detection algorithms. Consequently, for the PECG
sensors to become a standard diagnostic tool in clinical practice,
it is essential for future studies to specify the abilities of each
PECG sensor and the associated detection algorithms when de-
tecting each type of arrhythmia and conduction system disease.
The PECG sensors can potentially be used even for a 12-
lead ECG synthesis [98, 110, 111]. Their additional advantage
is that they can be used to obtain specific ECG leads for
specific purposes [112–114].
Because of an autonomic nervous system dysfunction,
COPD patients have been shown to exhibit decreased HR
variability compared to control subjects, as well as reduced
levels of all the linear exponents and a decreased short-term
fractal exponent of the intervals between beats [115]. The
power of the HR-related features for predicting exacerbations
remains to be investigated.
4.3 Empowering patients and personalization
How can we make the system for the remote monitoring of
COPD patients easy to use and able to adapt to each patient’s
specific needs? A recent systematic review [20] shows that
patients were Bgenerally satisfied and found the systems use-
ful to help them manage their disease and improve healthcare
provision.^ The review, however, indicates a number of us-
ability problems that need to be overcome in future research.
These include the short battery life, a confusing power supply,
and the need to provide real-time feedback. Based on previous
research by Botsis and Hartvigsen [116], the authors also em-
phasize that the security and confidentiality of the collected
data should be satisfied. Interestingly, the authors also state
that the lower compliance is related to the frequency and
timing of the data collection and transmission, which is carried
out at discrete time points during the day and requires effort
from the patients. It is to be expected that the automatic col-
lection and transmission of data will increase the patients’
compliance with the remote monitoring systems.
According to the study made by Gravil et al. [75], 80% of
patients would be happy to be treated at home for
uncomplicated exacerbations instead of being admitted to a
hospital. In their study, however, the patients were visited by
nurses who monitored adherence to the recommended treat-
ment and offered reassurance, support, and education. The
only measurements used were spirometry and SpO2, which
were applied by the nurses. If the patients were to use a remote
monitoring system on their own, we would expect the accep-
tance of the home treatment to be significantly lower. One of
the reasons for this could be technophobia, which according to
the American Telemedicine Association [117] can be reduced
among users by tailoring systems to the specific needs of each
user population. Furthermore, there is evidence that the pro-
motion of easy-to-use systems and more training sessions, to
make patients more familiar with the system, should improve
the acceptance of these remote monitoring systems [20, 118].
Contributing to the acceptance should also be the provision of
additional security that comes from the fact that the patients’
symptoms will be recognized early by the remote monitoring
system and that they will be contacted and treated if any de-
terioration occurs.
One important goal of any COPD monitoring system
should be to enable patients to better understand the disease,
to familiarize themselves with symptoms and ways to control
them, and to empower the patients to bemore involved in their
healthcare, so that they can recognize the exacerbations at an
early stage.
4.4 Monitoring and controlling physical activity,
exercise, and reference test
Patients with COPD have significantly lower levels of physi-
cal activity (PA) than healthy controls [119], and even lower
than people with some other chronic conditions [120]. Even
though PA is recommended for COPD patients (Sect. 2.3),
most patients do not follow these recommendations [67].
Remote monitoring may have a positive motivating effect on
COPD patients to increase PA [121, 122] by providing
counseling and feedback, but it is prudent to monitor COPD
patients’ physiological parameters (PaCO2, PaO2, ECG) dur-
ing PA also because of the health risks involved (see Sect.
2.3). For the remote assessment of PA, both questionnaires
and motion sensors, like step counters and accelerometers,
can be used, but a recent investigation showed that question-
naires provide overestimates of the true PA [123].
Questionnaires are mainly used for research purposes, es-
pecially in epidemiological studies. There have been more
than 15 different questionnaires developed for COPD patients
[67]. From the perspective of continuous monitoring, the
questionnaires can be implemented in an application for
PCDs and be used by the patients on an everyday basis (see
Sect. 4.5).
Pedometers are devices that count the number of steps.
From the number of steps counted, it is possible to estimate
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not only the distance traveled but also the energy expended.
However, these estimates lack precision, especially when the
walking is at slow speed, which is typical in patients with
COPD [67]. Despite being imprecise, there is evidence that
pedometers are motivating for patients to increase and main-
tain their levels of PAwhen used alone [124], or together with
a PCD application providing individualized activity goals and
allowing occasional telephone contacts with caregivers [122].
Accelerometers are devices that measure acceleration. The
measurements obtained with accelerometers reflect body
movement. For estimating PA levels and energy expenditure,
they can be combined with pedometers and physiological sen-
sors, e.g., HR and skin temperature, to provide valid estimates
of PA levels [67, 125].
It is useful to know that levels of PA cannot be accurately
predicted from resting lung-function parameters, i.e., spirom-
etry [67].
There are also reference tests for evaluating the progression
of the disease. One of them is the B6-min walk test^ during
which the patient walks the longest distance he/she can, while
his/her blood saturation is monitored with a pulse oximeter to
assess exercise-induced oxygen desaturation which has an
additional prognostic values besides the 6-min walk distance
[70]. There is evidence of a positive association between the
6-min walking distance and the PA [67].
4.5 Self-assessment
A questionnaire implemented on a PCD can be provided to the
patient to be filled in every day. They can include fields like
how much coughing, how much sputum production, how
much breathless—dyspnea, general feelings, PA assess- ment,
and other questions that can be found in existing
questionnaires.
The most comprehensive COPD-related questionnaires are
the Chronic Respiratory Questionnaire (CRQ) [126] and the
St. George’s Respiratory Questionnaire (SGRQ) [127] (online
[8]). The SGRQ’s score has been associated with anxiety and
depression, two major comorbidities in COPD.
The latest GOLD executive summary [30] considers CRQ
and SGRQ as being Btoo complex to use in clinical practice^
and promotes shorter measures, like the COPD Assessment
test, as more suitable. Still, the questionnaires used in the
research of the remote monitoring of COPD are diverse.
Some of the researchers have even developed their own ques-
tionnaires [21].
A drawback of self-reporting is that it can be difficult for
patients. There is evidence that only a minority of patients can
Blog discrete episodes of increased breathlessness, cough and
purulent sputum^ [128]. This is one of the reasons for prefer-
ring the continuous automatic monitoring of physiological
parameters instead of self-reporting.
4.6 Monitoring medication application and adherence
An appropriate medicament therapy can reduce COPD
symptoms, reduce the frequency and severity of exacerba-
tions, and improve health status and exercise capacity, but
Bexisting medications for COPD have not been shown con-
clusively to modify the long-term decline in lung function^
[66]. In particular, exacerbations are treated with broncho-
dilators, systemic corticosteroids, and antibiotics, and there
are new drugs developed all the time [129]. The cortico-
steroids can cause hypertension, which calls for blood
pressure measurements and ECG monitoring during corti-
costeroid therapy. Stopping regular medication, such as
diuretics and/or bronchodilators, on the patient’s own ini-
tiative might increase symptoms [7].
It has been suggested for more than 10 years now that
remote monitoring should be used as the Bgold standard^ for
medication adherence measurements [130], but how to effec-
tively monitor medication compliance and how to motivate
patients to take their medicaments are challenges that still
remain. PCD applications that provide reminders and feed-
back to patients could be useful as motivators. As for moni-
toring compliance, intelligent packaging for medicaments,
equipped with electronics for collecting and transmitting the
data about usage, can provide controlled access to medica-
ments in terms of keeping track of how many medicaments
have been used and at which times. This enables monitoring
of the adherence to the therapy, the evaluation of patterns of
medicament use, and monitoring the dose-response relation-
ship [130]. Obviously, smart packaging can be tricked into
tracking adherence since it is not able to detect whether the
pills are actually swallowed.
Perhaps the most impressive recent development in moni-
toring medication adherence, which cannot be easily tricked,
is the Proteus Digital Health ingestible sensor that measures
medication ingestion and adherence patterns in real time
[131]. It is a system of a 1-mm digestible chip and a patch
that picks up the signal from the chip and can also capture the
HR [132]. Another example of recent developments that are
particularly significant for COPD and asthma patients is
AstraZeneca’s inhaler device called Turbuhaler, which has
recently been accompanied by a monitoring device to monitor
the actuations of the inhaler [133].
A related problem is how to tailor medications to individual
needs. According to the GOLD: BEach pharmacological treat-
ment regime needs to be adapted to the patient (i.e., individu-
alized), guided by the severity of the symptoms, the risk of
exacerbations, comorbidities, drug availability, and the pa-
tient’s response^ [66]. This can be at least partially achieved
by using remote monitoring, for the purpose of titrating/
adjusting the treatment, or providing patients with personal-
ized advice. For example, in stable COPD, an increase in
FEV1 following a therapeutic trial of corticosteroids for
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several days is often taken as an indication of regular use for
these drugs [76].
4.7 Detection and classification of exacerbations
Signs are objective, whereas symptoms are subjective, evi-
dence of a health problem.
The symptoms of severe COPD exacerbations that require
hospitalization are [76]
1. Change in cough frequency.
2. Change in sputum production and appearance.
3. Increase in dyspnea at rest.
The signs of severe COPD exacerbations that require hos-
pitalization are [76]
4. Inability to speak one full sentence.
5. Temperature > 38.5 °C.
6. Ankle oedema.
7. Respiratory rate > 25/min.
8. HR> 110/min.
9. PaO2 < 8 kPa [75].
10. Worsening cyanosis.
11. Use of accessory muscles.
12. Loss of alertness.
13. PEF < 100 l/min.
All of these parameters are measurable at home. Parameter
12 is significant on its own, whereas parameters 3, 7, 8, 10,
and 11 are significant as a group [76]. It is important to note
that the exact thresholds in the previous list are not universally
accepted; studies in remote monitoring employ diverse exac-
erbation criteria [21], which might be one of the reasons for
the inadequate performance of decision support algorithms
(discussed in the next section).
The criteria for severe COPD exacerbations based on pa-
rameters that are normally measured in hospitals but can now
also be measured in the home environment with portable spi-
rometers, transcutaneous measurements, and portable ECG
devices are [76] FEV1 < 1 l, PaO2 < 8 kPa (60 mmHg),
SaO2 < 90%, PaCO2 ≥ 6.0 kPa (45 mmHg), and ECG abnor-
malities. Additional measurements for severe acute exacerba-
tion, which are currently not measurable at home, are chest
radiograph, white blood cell count ≥ 12,000, sputum stain/
culture, biochemistry (electrolytes, urea, glucose, etc.). The
life-threatening events are respiratory or cardiac arrest, confu-
sion or coma, PaO2 < 6.7 kPa (50 mmHg), PaCO2 ≥ 9.3 kPa
(70 mmHg), pH < 7.3.
COPD exacerbations can often be prevented [66]. It is
therefore desirable to predict or at least early detect signs
and symptoms of exacerbations. This can be done
automatically by using decision support systems featuring
the classification of patient states.
4.8 Decision support (exacerbation prediction
and detection algorithms)
In most of the existing remote-monitoring systems, the infor-
mation obtained is analyzed by health caregivers. Only some
of them provide automatic decision support systems [15],
stand-alone or in combination with human analysis. Figure 6
presents the COPD-related decision support systems data ob-
tained from two existing reviews [20, 21], and reports featur-
ing decision support that came after the reviews [84, 103,
134–137]. The most often used inputs are the self-reporting
of symptoms on a PCD, followed by pulse oximetry and spi-
rometry (Fig. 6a). ECG has been used in only two publica-
tions: as a source of the features for exacerbation prediction
[136], and to detect Bclinical alert^ (further details not provid-
ed) [138], whereas the PtcCO2 was not used at all.
Panel b shows that only about one quarter of the research
featuring decision support provides automatic data acquisi-
tion. This is related to the frequency of data acquisition and
analysis, which was almost exclusively on a daily basis, ex-
cept in [139] where it was 3 h, in [140] where the interval
could be varied depending on each patient’s needs, as well
as in [136], which is the only report featuring continuous data
processing. Patients’ compliance is affected by the frequency
and method of data acquisition, as discussed in Sect. 4.3, but
more importantly, it is not possible to detect immediate life-
threatening events without continuous monitoring.
Clinical decisions are traditionally based on a set of
predefined universal rules (see previous section). It is for that
reason that the approach most often utilized for detecting and
predicting exacerbation was by defining universal
(population-based) thresholds on obtained symptoms and
physiological parameters (panel c). These thresholds were
sometimes adjusted to individual patients’ needs, but the best
results were obtained by using more advanced classification
algorithms: linear discriminant classification [141], a
Bayesian network [140], a probabilistic neural network clas-
sifier [142], multilevel logistic regression [143], classification
and regression trees [144], k-means clustering [145], a state
machine combined with logistic regression [84], and a hybrid
classifier combining a support vector machine, random forest,
and a rule-based system [136]. The purpose is to classify the
patient’s status as being in exacerbation (detection) or as tran-
sitional towards exacerbation, i.e., the prodromal period
(prediction).
The reported accuracy in detecting exacerbations ranged
from 40 to 94%, the sensitivity from 6 to 80%, and the spec-
ificity from 61 to 95%. The best accuracy in the early detec-
tion of exacerbations is reported for the hybrid classifier with
10 measured parameters and a total of 25 features used as the
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inputs [136]. Nevertheless, by using only self-reported symp-
toms as inputs, and k-means clustering, it is possible to obtain
a sensitivity of 75% and 90% specificity for early exacerbation
detection [145]. Furthermore, a pulse oximeter alone in com-
bination with a classification algorithm can provide a high
predictive accuracy [84].
Only two studies [142, 145] reported using patients’ elec-
tronic health records, but these were developed only for the
purpose of the study and did not seem to be integrated into the
patients’ standard care.
Besides completely outperforming the threshold approach
and providing encouraging results, advanced classification al-
gorithms ensure that the classification is adapted to each pa-
tient, provide ranking of features based on their predictive
power [84], as well as the extraction of new rules [136]. For
a concise description of the predictive analytics methods used
in healthcare, the reader can refer to [21].
In addition to detecting exacerbations, it is beneficial to
assess their severity for the purpose of deciding between home
or hospital treatment.
4.9 Assessment of severity and deciding
between home or hospital treatment
The severity of an exacerbation is assessed crudely by
tachypnoea, tachycardia, the use of accessory respiratory mus-
cles, cyanosis, and evidence of respiratory muscle dysfunction
or fatigue (e.g., uncoordinated ribcage motion or paradoxical
movement of the abdominal wall during inspiration) [76]. If
the severity of an exacerbation is in doubt, it should always be
assessed in hospital. Referral to a hospital’s emergency depart-
ment is mandatory in the case of respiratory failure indicated
by the increased use of accessory respiratory muscles, para-
doxical movement of the abdominal wall during inspiration,
and significant deterioration in mental status.
Mild exacerbations of COPD are generally believed to rep-
resent an increase in symptoms, especially dyspnea, not nec-
essarily accompanied by increased cough and sputum produc-
tion, which might be more tenacious than usual. These
parameters can be obtained through a self-assessment (see
Sect. 4.5). Severe exacerbation, on the other hand, is associ-
ated with acute respiratory failure, especially in patients with
an impaired lung function, sometimes accompanied by hyper-
capnia [7], which can be obtained from a PaCO2 measure-
ment. Severe exacerbations cannot be treated at home, so if
detected, patients should be transported to a hospital.
There are no definitive clinical guidelines about whether
a patient should be cared for at home or in a hospital, and
physicians are often uncertain when making this decision.
The most important factors are the severity of the exacer-
bation, acute respiratory failure, the onset of new physical
signs (e.g., cyanosis, peripheral edema), and the failure of
an exacerbation to respond to initial medical management
[30]. Other factors that can be taken into account are cause
of the exacerbation (for example, severe pneumonia), a
coexisting disorder that requires admission, degree of dis-
ability, social factors like the degree of support in the com-
munity (e.g., whether the patient lives alone), patient’s his-
tory, and mental state [7, 75].
4.10 Detection of provoking and predictive factors
It is not clear which factors determine the development and
severity of an exacerbation [7]:
& It is commonly thought that viral and bacterial infections
of the tracheobronchial tree are the major causes of exac-
erbations in the later stages of disease [129]. The role of
bacterial and viral infections in COPD exacerbations is
still considered as controversial by some authors [7].
& Air pollution [66].
& There is some evidence that ozone concentration might be
slightly associated with additional hospital admissions [146].
& Poor nutrition, i.e., malnutrition, in combination with re-
spiratory muscle fatigue can aggravate the exacerbation.
& Drugs (especially tranquilizers).
& Stopping regular medication such as diuretics and/or bron-
chodilators on the patient’s own initiative can increase
Fig. 6 Overview of existing decision support systems. a Sensors used
(Other: video/audio (five systems), physical activity (four systems), ECG
(two systems), lung and heart sounds (one system), glucometer (one
system)). b Patient action needed for data acquisition or automatic data
acquisition. c Algorithms used. Total number of participant used in the
studies is 1866, whereas the average duration of the studies was
6.4 months
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symptoms, which means that the monitoring of medica-
tion compliance is important (Sect. 4.6).
& Inappropriate oxygen administration can aggravate an ex-
acerbation because of a reduction in the hypoxic respira-
tory drive.
& Conditions that can mimic or aggravate symptoms are
pneumonia, pulmonary hypertension, heart failure or ar-
rhythmias, pulmonary embolism, and pneumothorax.
& The cause of about one third of severe exacerbations of
COPD cannot be identified [66].
A study involving 64 patients with moderate-to-severe
COPD showed evidence that chronic hypercapnic respiratory
insufficiency (high PaCO2) and pulmonary hypertension are
predictive factors for hospitalization caused by COPD exac-
erbation [147]. Long-term oxygen therapy and perhaps even
long-term noninvasive mechanical ventilation at home are
possibly factors that reduce the risk of severe exacerbations,
since there is evidence that they reduce hospital admission in
COPD with chronic hypercapnia [148].
A study using the SGRQ showed that factors for predicting
frequent exacerbations were daily cough, daily wheeze (clin-
ical sign of exhaling difficulties caused by a narrowed tracheo-
bronchial tree), and daily cough and sputum together, and
frequent exacerbations in the previous year [149]. Another
study showed that SGRQ scores and poor quality of life are
associated with re-admission for COPD [150].
4.11 Educational programs
Even though there are reports that educational programs for
COPD patients can significantly reduce the utilization of
healthcare services and improve health status [151], they have
not been as actively promoted asmuch as programs for asthma
patients [76]. Single-topic programs are available (e.g.,
smoking cessation, long-term oxygen therapy, rehabilitation),
but there are insufficient integrated educational materials in-
corporating all the aspects of disease management [151].
Educational programs should improve people’s knowledge
about the disease process and its treatment and should also
motivate patients to change behavior and lifestyle, with the
goal of improving their quality of life [151].
5 Notes about normal and pathological
ranges and changes in the measured
physiological signals
5.1 SaO2 and PaO2
The SaO2 normal range (two standard deviations (SDs)
around mean) for adults aged < 70 years at sea level is 94–
98%. For young adults (age 18–24), the 2SDs PaO2 range is
11.98–14.82 kPa (89.3–110.5mmHg). The lower limit for this
range decreases significantly with increasing age [152], e.g.,
the range for 64 years old and more is 9.02–14.76 kPa (67.3–
110.1 mmHg) [47]. Additionally, the PaO2 is 0.8 kPa
(6 mmHg) lower in the supine position than in the upright
position.
Oxygen demand and oxygen delivery increase during ex-
ercise and reduce during rest and sleep. Hypoxemia (too low
PaO2) can be defined as PaO2 below the normal lower limit,
but most authors suggest values of less than 8 kPa
(60 mmHg), or SaO2 of 90% [47].
The most common recommendation for patients with
COPD is that oxygen is admitted if the resting awake PaO2
is less than 7.3 kPa (55 mmHg), or if it is 7.3–7.9 kPa (55–
59 mmHg) in the presence of an elevated hematocrit (55%) or
elevated right ventricular pressure evident from ECG [55].
5.2 PaCO2
The reference range for PaCO2 is 4.6–6.1 kPa (34–46 mmHg)
for a healthy adult of 18–38 years [47]. Values above 6.1 kPa
are out of the normal range, but values up to 6.7 kPa can be
accomplished by holding the breath.
5.3 Body temperature
In humans, the traditional normal value for the oral tempera-
ture is around 37 °C [153]. Various parts of the body are at
different temperatures, and the magnitude of the temperature
difference between the parts varies with the environmental
temperature [153]. There are a lot of other variables that can
influence temperature measurements, such as the measure-
ment site, time of the day, age, etc. [95].
A body temperature higher than 38.5 °C is one of the fac-
tors indicating severe exacerbations [76].
5.4 Electrocardiogram
With the development of pulmonary heart disease due to COPD,
the following changes might be seen in a routine ECG [154]:
& The P wave axis is farther right than + 75°.
& Any of the right ventricular hypertrophy criteria.
& Late R wave progression in precordial leads.
& Low voltage.
& Abnormal Q waves in the inferior or anterior leads.
& Supraventricular arrhythmias, especially atrial tachycar-
dia, multifocal atrial tachycardia, and atrial fibrillation.
& Ventricular arrhythmias [155].
On the other hand, some more acutely presenting ECG
changes may signal higher risk for the patient. It is known that
patients with COPD have higher rates of cardiovascular
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diseases and consequently higher incidence of cardiovascular
causes of mortality [63–66].
Some ECG changes can be attributable to acute
overloading of the right ventricule of the heart which may be
seen in acute pulmonary embolism or acute respiratory failure,
such as
& S1Q3 pattern in standard leads.
& Acute right bundle branch block.
& Right axis deviation [155].
but some more subtle changes may contribute to the impor-
tance of the ECG changes in defining the risk of the patients
with otherwise stable COPD:
& Prolongation or shortening of the heart rate corrected QT
interval (QTc) suggests higher incidence of sudden cardiac
death. It has been shown that these changes may occur
more often in patients with COPD [156].
& Reduced heart rate variability is also a marker of sudden
cardiac death and has been connected to patients with
COPD.
& Dispersion of the QT interval in ECG recordings shows
potential to foresee the adverse events and has been ap-
preciated more often in patients with COPD [157].
Supraventricular arrhythmias occur frequently in patients
with COPD [63]. Most often, they comprise atrial tachycardias,
especially multifocal atrial tachycardia, atrial fibrillation, and
atrial undulation which are often chronic. Ventricular tachycar-
dias such as non-sustained ventricular tachycardia may depict
patient’s higher risk for adverse events. Sustained ventricular
tachycardia and ventricular fibrillation are arrhythmias that need
to be terminated instantaneously. Arrhythmias are in general life-
threatening events and can lead to dangerous complications. For
instance, patients with COPD and multifocal atrial tachycardia
have higher mortality rates [158].
Cardiac arrhythmia is a group of conditions in which the
heartbeat is irregular, too fast, or too slow. If a heartbeat is
above 100 beats/min in adults, it is called tachycardia and a
heartbeat that is below 60 beats/min is called bradycardia. To
distinguish between different arrhythmia types, other diagnos-
tic procedures must be used in addition to the HR analysis.
The ECG can show signs of myocardial ischemia, specifi-
cally ST segment and T wave changes, as well as signs of
myocardial infarction, specifically changes in the QRS pat-
tern. However, not all patients with acute or previous myocar-
dial infarction exhibit ECG changes [159, 160].
5.5 Arterial blood pressure
BHypertension is likely to be the most frequently occurring
comorbidity in COPD and can have implications for
prognosis^ [30]. The pressure in the aorta and in the brachial
and other large arteries in a young adult human rises to a peak
value (systolic pressure) of about 120 mmHg during each
heart cycle and falls to a minimum (diastolic pressure) of
about 70 mmHg [161]. Conventional notation for the arterial
pressure is systolic pressure over diastolic pressure, e.g. 120/
70 mmHg. There are, however, a number of variables that can
influence normal blood pressure values. For details, the reader
is referred to [161] or similar literature.
There are different guidelines that usually define the pres-
sure intervals specifying different hypertension severities.
Stage 1 hypertension is defined as Bclinical blood pressure
of 140/90 mmHg or higher and subsequent ambulatory blood
pressure monitoring daytime average or home blood pressure
monitoring average blood pressure is 135/85 mmHg or
higher^ [162]. Therefore, in remote settings, we can consider
135/85 mmHg as a general threshold for hypertension.
5.6 Spirometry output
The presence of a post-bronchodilator FEV1/FVC of less than
0.70 confirms the presence of COPD [66]. The severity of
COPD can be categorized based on FEV1 (percent of predict-
ed): mild ≥ 70, moderate 50–69, severe < 50 [76], or accord-
ing to GOLD: mild ≥ 80, moderate 50–79, severe 30–48, very
severe < 30. For the complete list of reference values in spi-
rometry, see [91].
5.7 Respiratory rate
One of the signs of COPD exacerbation is a respiratory rate
over 25/min [76]. A normal adult human at rest breathes 12–
15 times a minute [163].
6 Conclusion and future development
The guideline for home treatment and management of mild
COPD exacerbations, as specified by the European
Respiratory Society [76], states that patients need to be
reassessed every 48 h for worsening of symptoms, signs,
and measurements. With the inclusion of continuous monitor-
ing, this interval can be prolonged and the home treatment of
exacerbations made more secure.
Two crucial improvements to the current remote-monitoring
systems are enabling the continuous monitoring of the most
important physiological parameters and enabling real-time de-
cision support based on advanced classification algorithms,
which are still to prove their clinical reliability. This will make
it possible to detect life-threatening events in real time, conse-
quently reducing mortality and hospitalization. Other expected
consequences are an increase in the cost efficiency and an
improvement of patients’ compliance with the monitoring.
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Furthermore, continuous monitoring can provide new insights
into the patients’ states, like detecting transitions from a deteri-
orated to the normal state that happened without an interven-
tion, and information about the durations of the exacerbations.
Moreover, the decision support algorithms can rank features by
their predictive power and even create new rules, consequently
enriching clinical knowledge.
All the presented devices are already mature enough to be
used for remote monitoring. Only in the case of transcutane-
ous measurements of O2 and CO2, the high costs of the de-
vices currently hinder them from being placed in a large pro-
portion of COPD patients’ homes. Still, as we discussed in
Sect. 4.1, they could be efficiently and usefully applied by
nurses visiting patients in their homes, and shared between
multiple patients.
In the future, we can expect the design of the available de-
vices to further improve in terms of lower power usage, the
batteries will have higher capacities, enabling longer stand-
alone periods for wireless sensors, and the electronics will im-
prove, enabling further minimization. The level of user accep-
tance should be considered even during the design time, because
tailoring the systems to target groups’ specific needs, reduces
technophobia, and consequently improves acceptance.
At the signal-processing level, the obtained physiological
signals are usually much more contaminated with noise and
artifacts in the case of remote monitoring, with respect to
those obtained in hospital settings. How to remove the arti-
facts and noise efficiently is still an open question, and algo-
rithms are currently being developed for this purpose, which
should run efficiently on sensors or PCDs. The possibility of
having a lot of wireless sensors, either worn by the subjects or
placed in subjects’ environments, that can produce the data
quickly (e.g. ECG, 1000 samples per second) also imposes
specific challenges in the area of wireless networks, which
should be able to communicate the data without significant
losses, and handle the devices in a plug-and-play manner.
The sensitive nature of medical data imposes a need to
ensure the privacy and security of the obtained measurements
at all levels, from sensors to the cloud, and in all communica-
tion channels. This is still an open issue for which algorithms,
frameworks, and standards are currently being developed.
With the future developments of all the necessary technol-
ogy, we can expect remote monitoring systems for COPD, as
well as for other diseases, to become integrated into the
healthcare system, which will reduce costs and improve care.
Additionally, remote monitoring enables the treatments and
care to be tailored to each patient’s needs based on their pre-
dicted response and individual risks, which is the core require-
ment of personalized medicine.
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Summary points
• Physiological parameters significant for COPD patients in remote
settings are ECG, PaO2, PaCO2, spirometry, respiration rate, body
temperature, blood pressure, and weight.
• Cardiovascular diseases are the most frequent comorbidities with
COPD.
• Patch ECG monitors are a promising technology for ECG
monitoring and can also provide respiration rate, which is very useful
for COPD patients.
• Respiratory rate can also be obtained from pulse oximetry.
• Hypertension is a frequent comorbidity but can also be caused by
medicaments, whichmeans that it is important to measure blood pressure.
• Spirometry in acute situations is not very informative. It is used
mainly in the diagnosis of COPD as well as in the assessment of its
severity, progression, and prognosis. Peak expiratory flow meters are
simpler and less expensive than full spirometers, but useful for COPD.
• Air pollution has been shown to be a major COPD risk factor, but
smoking is first.
• A body temperature higher than 38.5 °C is one of the factors
indicating severe exacerbation.
• As a consequence of respiratory failure either only PaO2 is
decreased, or both PaO2 and PaCO2 are abnormal (low PaO2 and high
PaCO2).
• PetCO2 is not a reliable estimate of the PaCO2 for COPD patients.
PtcCO2 has recently become the preferred way of estimating PaCO2.
PtcCO2 is continuous and noninvasive.
• Oxygen therapy can cause or increase hypercapnia.
• Early recognition of exacerbations and prompt treatment improves
recovery, reduces the risk of hospitalization, and is associated with a
better health-related quality of life. It is therefore important to detect the
first signs and symptoms of exacerbations or to predict them.
• For the early detection or prediction of exacerbations, it is essential to
use more advanced classification algorithms (e.g., random forest, support
vector machine, logistic regression) than simple thresholding.
• For uncomplicated exacerbations, patients can be treated at home,
and they prefer to be treated at home.
• Individual continuous monitoring enables prompt personalized
treatments, which is recognized as a necessity for improved medical
care, i.e., for personalized medicine.
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